|
Causative
Agent
Routes of Exposure
Infective Dose &
Infectivity
Incubation Period
Clinical Effects
Lethality
Transmissibility
Primary Contaminations & Methods of Dissemination
Secondary Contamination & Persistence of organism
Decontamination &
Isolation
Laboratory testing
Therapeutic Treatment
Prophylactic Treatment
Differential Diagnosis
References
Causative
Agent:
Eastern Equine Encephalitis (EEE) is a
mosquito-borne illness caused by an alphavirus of the
Togaviridae family.
Routes of Exposure:
Humans are primarily exposed to EEE through the bite of an
infected mosquito.
Infective Dose &
Infectivity:
The
infective dose is unknown. All people are considered
susceptible though children are more likely to be severely
affected.
Incubation Period:
The incubation period is varies from 5-15 days.
Clinical Effects:
The illness is characterized by rapid onset of high fever,
vomiting, stiff neck, and drowsiness. Children
frequently manifest generalized, facial, or periorbital edema.
Motor involvement with paresis is common during the acute
phase of the illness. Major disturbances of autonomic
function, such as impaired respiratory regulation or excess
salivation may dominate the clinical picture. Adults
typically exhibit a febrile prodrome for up to 11 days before
the onset of neurological disease; however, illness in
children exhibits a more sudden onset. Up to 30% of
survivors are left with neurological sequelae such as
seizures, spastic paralysis, and cranial neuropathies.
Cognitive impairment ranges from minimal brain dysfunction to
severe dementia.
Lethality:
Fatality
rates for EEE are estimated to be from 50% to 75%.
Mortality rates are highest among young children and the
elderly.
Transmissibility:
EEE infection occurs when a person is bitten by an infected
mosquito. The virus is not directly transmitted from
person-to-person.
Primary contaminations & Methods of Dissemination:
As a bioterrorism weapon, EEE would most likely be delivered
via aerosolization.
Secondary Contamination & Persistence of organism:
Secondary transmission does not occur and EEE particles are
not considered to be stable in the environment.
Decontamination &
Isolation:
-
Patients
– Standard precautions should be practiced and enteric
precautions are appropriate until enterovirus
meningoencephalitis is ruled out. Specific isolation
procedures are not indicated.
-
Equipment,
clothing & other objects
– 0.5% hypochlorite solution (one part household bleach and
9 parts water = 0.5% solution) is effective for
environmental decontamination.
Laboratory testing:
Clinical laboratory findings in patients with EEE often
demonstrate an early leukopenia followed by a leukocytosis.
Elevated opening pressure is commonly noted on lumbar
puncture, and in children, especially, the CSF lymphocytic
pleocytosis may reach a cell count of thousands of mononuclear
cells per microliter. Specific diagnosis of EEE depends
on virus isolation or serologic testing in which rising titers
of HI, CF, or neutralizing antibodies are observed. IgM
antibodies are usually detectable in acute-phase sera.
Therapeutic Treatment: There is no specific therapy. Patients
who develop severe illness may require anticonvulsant and
intensive supportive care to maintain fluid and electrolyte
balance, adequate ventilation, and to avoid complicating
secondary bacterial infections.
Prophylactic Treatment: An investigational formalin-inactivated vaccine
is available, but it is poorly immunogenic.
Differential Diagnosis: The differential diagnosis includes a number of
infections including cytomegalovirus, herpes simplex
encephalitis, St. Louis encephalitis, West Nile encephalitis,
Western equine encephalitis, Venezuelan encephalitis, malaria,
Naegleria infection, leptospirosis, lyme disease, cat
scratch disease, bacterial meningitis, tuberculosis, and
fungal meningitis.
References:
-
Chin J.
Control of Communicable Diseases Manual, Seventeenth
Edition, American Public Health Association; 2000.
-
Smith JF,
Davis K, Hart MK, et al. Viral Encephalitides. In: Zajtchuk
R, Bellamy RF, eds. Medical Aspects of Chemical and
Biological Warfare. Washington, DC: Office of the Surgeon
General, U.S. Department of the Army; 1997:561-589.
For more
information call (602) 364-3289 |